Dogwood Therapeutics
DWTX
25 hedge funds and large institutions have $486K invested in Dogwood Therapeutics in 2022 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 5 closing their positions.
180% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 5
47% more funds holding
Funds holding: 17 → 25 (+8)
6.6% less ownership
Funds ownership: 13.63% → 7.03% (-6.6%)
13% less call options, than puts
Call options by funds: $65K | Put options by funds: $75K
90% less capital invested
Capital invested by funds: $4.8M → $486K (-$4.32M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$1.13M |
| 2 |
Renaissance Technologies
New York
|
+$995K |
| 3 |
Walleye Capital
New York
|
+$845K |
| 4 |
VF
Virtu Financial
New York
|
+$269K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$231K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
Masters Capital Management
Atlanta,
Georgia
|
-$2.75M |
| 2 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$170K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$129K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$6K |
DWTX Hedge Fund Activity: Q3 2022 in Review
25 of the 5,829 institutional investors tracked by Wall St. Rank reported a position in Dogwood Therapeutics (DWTX) for Q3 2022, worth a combined $486K — down 90% from $4.8M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new DWTX positions and 5 closed out — a net gain of 9 holders — while 3 added to existing stakes and 0 trimmed.
The largest buyer was Warberg Asset Management, opening a new position worth an estimated $1.13M. The largest seller was Masters Capital Management, exiting entirely with an estimated $2.75M sold.
- 25 institutional investors held Dogwood Therapeutics (DWTX) as of Q3 2022, up from 17 in Q2 2022.
- Funds reported $486K of Dogwood Therapeutics stock for Q3 2022, down 90% quarter-over-quarter.
- 14 funds opened new Dogwood Therapeutics positions in Q3 2022 and 5 closed out, a net change of +9 holders.
- The largest Dogwood Therapeutics buyer in Q3 2022 was Warberg Asset Management, an estimated $1.13M added.
- The largest Dogwood Therapeutics seller in Q3 2022 was Masters Capital Management, an estimated $2.75M sold.
Based on aggregated 13F filings for Q3 2022.